肠道微生物群和动脉样硬化
William Fusco1,2,3, Timon Adolph4, Giovanni Cammarota1,2,3
1Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Gut
|July 11, 2025
概括
肠道微生物群通过微生物代谢物和与脂质通路的相互作用影响动脉样硬化发展. 调节肠道细菌显示出治疗这种慢性炎症性血管疾病的潜力.
科学领域:
- 心血管科学 心血管科学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 动脉样硬化是一种慢性炎症性动脉疾病.
- 传统上与脂质疾病相关,现在已经认识到脂质独立的途径.
- 新出现的证据表明,胃肠道微生物群与动脉样硬化发展有关.
研究的目的:
- 探索肠道微生物群在动脉样硬化中的作用.
- 了解将肠道细菌与血管炎症联系在一起的机制.
- 评估微生物群调节的治疗潜力.
主要方法:
- 对动脉样硬化患者肠道微生物群组成的临床研究的分析.
- 研究微生物代谢物对血管炎症的影响.
- 对微生物向干预措施的临床前研究的审查.
主要成果:
- 在动脉样硬化,心血管疾病和中风中观察到改变肠道微生物群和肠道中的口腔细菌.
- 微生物代谢物如内毒素和三甲基胺N-氧化物促进动脉样硬化;一些托衍生物可能具有保护作用.
- 肠道微生物群与脂质代谢相互作用,影响脂质的吸收/储存,并有助于血管衰老.
结论:
- 肠道微生物群是动脉样硬化中血管炎症的关键调节者.
- 肠道中的宿主微生物相互作用为动脉样硬化提供了未来的治疗点.
- 像益生菌和益生菌这样的干预措施显示出有前途,主要是在临床前的环境中.
相关概念视频
Atherosclerosis I: Introduction
92
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
92
Anatomy of the Intestines
74.1K
Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
74.1K
Coronary Artery Disease I: Introduction
60
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
60
Atherosclerosis III: Management
40
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
40
Inflammation
55.3K
Overview
55.3K
Coronary Artery Disease II: Pathophysiology
40
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
40


